Salmonella typhimurium bacteriophage STP-2 and use thereof for inhibiting proliferation of Salmonella typhimurium
Inventors
Yoon, Seong Jun • JUN, Soo Youn • Son, Jee Soo • Paik, Hyoun Rok • Kim, Beom Seok • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12114664-B2
Publication Date
2024-10-15
Expiration Date
Abstract
The present invention relates to a Siphoviridae bacteriophage STP-2 (Accession number: KCTC 12853BP) isolated from nature and characterized by having the ability to destroy Salmonella Typhimurium and having a genome represented by SEQ ID NO:1; and to a method for preventing and treating diseases caused by Salmonella Typhimurium using Siphoviridae bacteriophage STP-2 containing the same as an active ingredient.
Core Innovation
Siphoviridae bacteriophage STP-2 (KCTC 12853BP) is isolated from nature and has a genome represented by a sequence as set forth in SEQ ID NO: 1. The bacteriophage has an ability to kill Salmonella Typhimurium and kills a substantial number of Salmonella Typhimurium strains while not killing selected non-target bacteria.
The document reports inhibition of Salmonella growth in culture and activity that reduces Salmonella infection outcomes in animal models. It also describes a composition comprising Siphoviridae bacteriophage STP-2 for preventing and treating a disease caused by Salmonella Typhimurium in an animal other than a human.
Formulation forms explicitly described include a disinfectant, a drinking-water additive, and a feed additive. The document reports outcomes such as reduced infection indicators, reduced diarrhea/secretion, and reduced mortality when using phage-containing preparations.
Claims Coverage
The only independent claim covers a prevention and treatment method for a disease caused by Salmonella Typhimurium via administering a specific phage-based composition to an animal other than a human. It is grounded on three inventive elements: the Siphoviridae bacteriophage STP-2 with killing ability, the genome represented by SEQ ID NO: 1, and the specific deposit accession number KCTC 12853BP.
Non-human administration of STP-2 to prevent and treat Salmonella Typhimurium disease
Administering to an animal other than a human a composition to prevent and treat a disease caused by Salmonella Typhimurium.
Siphoviridae bacteriophage STP-2 as active ingredient with killing ability
Using Siphoviridae bacteriophage STP-2 as the active ingredient, the bacteriophage having an ability to kill Salmonella Typhimurium.
Genome represented by SEQ ID NO: 1 and deposited as KCTC 12853BP
Employing a Siphoviridae bacteriophage STP-2 with a genome represented by a sequence as set forth in SEQ ID NO: 1 and deposited as accession number KCTC 12853BP.
Claim coverage centers on a phage-based prevention and treatment method that requires administering an animal (other than a human) composition whose active ingredient is Siphoviridae bacteriophage STP-2 that can kill Salmonella Typhimurium, with the phage defined by SEQ ID NO: 1 and the deposit KCTC 12853BP.
Stated Advantages
Reduces Salmonella infection outcomes in animal models, including diarrhea/secretion.
Reduces mortality in a chicken-feeding study with phage-containing preparations.
Kills Salmonella Typhimurium while not killing selected non-target bacteria.
Documented Applications
Preventing and treating a disease caused by Salmonella Typhimurium in animals other than humans (including weaning pigs and chicks).
Use in formulation forms including a disinfectant, a drinking-water additive, and a feed additive for managing Salmonella Typhimurium infection outcomes in animals.
Interested in licensing this patent?